C-ErbB-2 Oncoprotein antibody

Details for Product No. ABIN965710
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
(1), (1), (1), (1)
Pubmed 7 references available
Quantity 5 mL
Shipping to United States (Change)
Availability Will be delivered in 5 to 7 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN965710
192.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Synthetic human c-erbB-2 oncoprotein from intracytoplasmatic part of the c-erbB-2 oncoprotein.
Specificity This antibody is specific against human c-erbB-2 oncoprotein.
Purification Prediluted.
Background Purified immunoglobulin fraction of rabbit antiserum prediluted in Primary Antibody diluting Buffer pH 7.6.
Research Area Cancer
Application Notes This antibody is prediluted for Immunohistochemistry use.
Staining Procedure: The prediluted antibody can be used on frozen cryostat sections as well as formalin-fixed paraffin-embedded tissue sections. For paraffinembedded tissue sections, we recommend an incubation time and temperature of 30 minutes at 37°C for this antibody, when used in conjunction with an immunoperoxidase staining kit. Prolonged fixation in buffered formalin can destroy the epitope.

Recommended Positive Control: Breast AdenoCarcinomas, Ovary, Gastrointestinal Tract

Restrictions For Research Use only
Format Liquid
Concentration 0.007 mg/ml.
Storage 4 °C
Product cited in: Slamon, Clark, Wong et al.: "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene." in: Science (New York, N.Y.), Vol. 235, Issue 4785, pp. 177-82, 1987 (PubMed).

Varley, Swallow, Brammar et al.: "Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis." in: Oncogene, Vol. 1, Issue 4, pp. 423-30, 1988 (PubMed).

Bouchard, Lamarre, Tremblay et al.: "Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene." in: Cell, Vol. 57, Issue 6, pp. 931-6, 1989 (PubMed).

Wright, Angus, Nicholson et al.: "Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer." in: Cancer research, Vol. 49, Issue 8, pp. 2087-90, 1989 (PubMed).

Barnes: "Breast cancer and a proto-oncogene." in: BMJ (Clinical research ed.), Vol. 299, Issue 6707, pp. 1061-2, 1990 (PubMed).

May, Mouriesse, May-Levin et al.: "Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression." in: British journal of cancer, Vol. 62, Issue 3, pp. 430-5, 1990 (PubMed).

Soomro, Shousha, Taylor et al.: "c-erbB-2 expression in different histological types of invasive breast carcinoma." in: Journal of clinical pathology, Vol. 44, Issue 3, pp. 211-4, 1991 (PubMed).

Validation Images
Did you look for something else?
back to top